PTT >180 seconds

From Renee Nutting: Is a PTT of >180 seconds always the result of heparin contamination or would such a result ever be medically desirable for a patient? Hello, Renee, and thank you for your question. A partial thromboplastin time (PTT) of >180 seconds, or one at the limit of instrument measurement, is likely an indication of […]

Comments (0)

Anticoagulant Therapy

Jan 12 2013

george

Reprise: Switching to Anti-Xa

Reviewing Sue Bergs‘ March 23, 2012 post asking, How Many Use the Anti-Xa?, I noticed the comment appended by “Istano” asking for data on switching from PTT to anti-Xa heparin assay for routine heparin monitoring. My answer was somewhat incomplete, so I thought I should connect this question with Marisa Marques, MD‘s June 20, 2012 question, Do You Use […]

Comments (0)

Anticoagulant Therapy

Jan 10 2013

george

Correction to December 6 Post

A note from my friend and colleague, John Landis, who retired from the Clinical Laboratory Science faculty at Ferris State University in Big Rapids, Michigan a few years ago: “I just read the new Cheat Sheet and saw the question from Scott Millerand your response. Scott is a graduate of my Ferris State program, but he works at St Mary’s of Saginaw not Grand Rapids. […]

Comments (1)

Anticoagulant Therapy

Dec 29 2012

george

Apixaban Cleared for Afib

After a lengthy delay, the US Food and Drug Administration (FDA) cleared apixaban (Eliquis®, Bristol-Myers Squibb/Pfizer) for prevention of stroke in non-valvular atrial fibrillation on 12.28.12. Apixaban is an oral direct anti-Xa anticoagulant and joins rivaroxaban and dabigatran (a direct thrombin inhibitor) as the third new oral anticoagulant cleared since 2009. Details appear in TheHeart.org.

Comments (0)

Anticoagulant Therapy

Dec 24 2012

george

Dabigatran Contraindicated for Heart Valves

On 12.20.12, the US Food and Drug Administration warned that dabigatran should not be used to prevent stroke in patients with mechanical heart valves. The FDA’s announcement was preceded by a Boehringer Ingelheim press release detailing the contraindication. Here is Boehringer’s new statement: “The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted […]

Comments (0)

Anticoagulant Therapy

Dec 24 2012

george

Extended Apixaban Therapy Reduces Recurrent DVT

According the results of a randomized control trial involving almost 2500 patients reported in the New England Journal of Medicine, twelve months of treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) at either of two dosages, given after six to 12 months of anticoagulation to treat venous thromboembolism (VTE), significantly lowered the risk of recurrent VTE compared with placebo. […]

Comments (0)

Anticoagulant Therapy

Dec 23 2012

george

Rivaroxaban Equivalent to Enoxaparin for DVT & PE

Here is a link to the latest EINSTEIN findings comparing rivaroxaban with enoxaparin for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) reportedDr. Harry Buller at the American Society for Hematology meeting on 12.11.12 in Atlanta, Georgia.

Comments (0)

Anticoagulant Therapy

Dec 7 2012

george

FDA Requires Precise Heparin Label

Elaine Benoit, Precision BioLogic, sent an FDA alert regarding a heparin label change. “This label change will require manufacturers of Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP to clearly state the strength of the entire container of the medication followed by how much of the medication is in 1 milliliter (mL). These modifications […]

Comments (0)

Anticoagulant Therapy

Dec 6 2012

george

Anti-Xa Calibrators

This post comes from Scott Miller, St. Mary’s of Michigan: We will soon be validating our activated partial thromboplastin time (APTT, PTT) heparin therapeutic range by using a comparison between an anti-Xa assay and APTTs run with our new lot of APTT reagent. I have always understood that when calibrating an anti-Xa assay for this procedure, one […]

Comments (0)

Anticoagulant Therapy

Dec 4 2012

george

Summary of Anticoagulant Therapy Guidelines

Shirlyn McKenzie, PhD, University of Texas Health Science Center at San Antonio, and I developed the following summary for the clinical applications of anticoagulant therapy. Dr. McKenzie will use this for a PA lecture. Please review and offer your suggestions, corrections, or updates. Percutaneous intervention (PCI, cardiac catheterization): use IV anti-glycoprotein IIb/IIIa agent during procedure such […]

Comments (0)

Anticoagulant Therapy

Anticoagulant Therapy

PTT >180 seconds

Reprise: Switching to Anti-Xa

Correction to December 6 Post

Apixaban Cleared for Afib

Dabigatran Contraindicated for Heart Valves

Extended Apixaban Therapy Reduces Recurrent DVT

Rivaroxaban Equivalent to Enoxaparin for DVT & PE

FDA Requires Precise Heparin Label

Anti-Xa Calibrators

Summary of Anticoagulant Therapy Guidelines

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question